Article
Highlights from Day 3 at ACR24 included the plenary session presentation on Nipocalimab (previously reviewed), but the big highlight was the Lupus Nephritis guideline recommendations.
All News
Article
This has been an interesting ACR meeting in terms of PMR updates. I would argue that we are still far too wedded to glucocorticoids only in the management of PMR. Yes, some patients will do fine with just glucocorticoids but we persist far too long with a glucocorticoid only strategy in others who clearly need an alternative as glucocorticoid adverse events multiply.
Article
Lots of lupus research and the New ACR Guidelines on Lupus Nephritis management were presented today. These and other highlights as featured on our Twitter (X) feed from ACR24 in Washington, DC.
Janet Pope
Tweet
It is NO LONGER a ACCEPTABLE
To NOT consider
#MMF or #Cyclo + another proven #Rx
Added to
#HCQ and #tapering /limiting #glucocorticoids
RCTs in #lupus #nephritis support this
? Is which to add
#belimumab
#CNI #volclosporin
#obinutuzimab
#ACR #ACRbest @RheumNow @ACRheum https://t.co/a7WMFfCyXl
Dr. John Cush
Tweet
RheumNow’s expanded coverage of #ACR24 is sponsored in part by Bristol Myers Squibb and UCB. All content is chosen by RheumNow & its faculty
Dr. John Cush
Tweet
Paraoxonase-1: Possible Biomarker for Progression to RA
Dr. Jonathan Kay discusses abstract 0464, Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population,… https://t.co/yhcCrrvjxH https://t.co/caf5dUvrOQ
Dr. John Cush
Tweet
JAK-pot! How fast do DMARDs work?
Dr. Mike Putman interviews Dr. Kim Lauper about abstract 0501, How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients… https://t.co/GO9EwyrVpV https://t.co/lELE5SJW5i
Dr. John Cush
Tweet
PREDICT-SpA: Evaluating the influence of gender on disease assessment tools
Dr. Sheila Reyes reports on abstract 0571, Gender-specific Performance of Disease Activity Assessment Tools in Axial Spondyloarthritis: Ancillary Analysis of the PREDICT-SpA Study, presented at #ACR24.… https://t.co/EGlCap6pEw
Caoilfhionn Connolly
Tweet
@DrLisaCS distills the challenges of MCTD 👇
🔵Clinical phenotyping key to improve patient outcomes
@jhrheumatology @RheumNow #acr24
https://t.co/APfXPwxvfE
Dr. John Cush
Tweet
Continuing or Stopping Low Dose Glucocorticoids in GPA
Dr. Mike Putman reports about plenary session abstract 0774 (the TAPIR study) about how and when patients can stop steroids in GPA. #ACR24
https://t.co/OWqN0jmkc1 https://t.co/foOaVRtGiV
Dr. John Cush
Tweet
RheumNow’s expanded coverage of the #ACR24 meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its Faculty.
Dr. John Cush
Tweet
RheumNow Day 3 Recap: ACR Convergence 2024 Highlights https://t.co/jFIATPKlp7
Richard Conway
Tweet
I've shared some thoughts on @RheumNow on methotrexate, tocilizumab, and baricitinib in PMR based on #ACR24 https://t.co/WXiW1nLN4k
Richard Conway
Tweet
TNFis preventing cancer compared to placebo, and JAKi being neutral to placebo and maybe preventing haem cancers also. #ACR24 abstract 0989 was certainly provocative. I've shared my thoughts on @RheumNow https://t.co/yQFoUGifEN
Antoni Chan MD (Prof)
Tweet
Pathophysiological pathways in neuropsychiatric SLE. 2 components:
-Ischaemic
-Inflammatory
Zahi Touma @RheumNow #ACR24 https://t.co/wwlSSSpOIU
Eric Dein
Tweet
Great project by @kekuchinad to evaluate how PFTs bias our assessment and contribute to disparities
@CaoilfhionnMD
@jhrheumatology @BayviewMedicine
@RheumNow #ACR24
https://t.co/b5pAn3e9AR https://t.co/opzWrZ1NH5
Dr. John Cush
Tweet
Potential Impact of Weight Loss Drugs in Rheumatic Diseases
Dr. Arthur Kavanaugh highlights a session regarding weight loss and improvement in disease outcomes, specific weight loss drugs (SGL-2 and GLP-1), along with downsides when patients stop these medications. Reporting… https://t.co/Ilu2FXK2xi https://t.co/7CKSnfuey4
Richard Conway
Tweet
Yang et al. Cranial vessel wall MRI in GCA. Quantitated with PEG score. PEG score ocular GCA>non-ocular GCA>non-GCA. Decreases with treatment. @RheumNow #ACR24 Abstr#2650 https://t.co/e26urOpb7V https://t.co/eekQbzmKYm
Eric Dein
Tweet
A#2651
Vasculitis w VEXAS
81 men, median age 67 - 27% had evid of vasculitis, variable size vessel
22% SVV- 17/18 cutaneous, one peritubular capillaritis on renal bx
2.5% MVV (2 cutan), LVV (2 carotid thickening, 1 had +TA bx), ANCA+
@RheumNow #ACR24 https://t.co/puablIBLCP
Mrinalini Dey
Tweet
What factors are assoc with uptake of newer meds in RA?
➡️Incr use of b/tsDMARDs over 10yrs
➡️Use of newer drugs lower in older ppl, socioeconomic deprived & Asian/Black ppl
Could this indicate disparities in access to meds? How can we best address this?
Ab2608 #ACR24 @RheumNow
